Abstract：
Parkinson\'s disease is one of the most common neurodegenerative diseases affecting the ageing population, with a prevalence that has doubled over the last 30 years. As the mechanism of the disease is not fully elucidated, the current treatments are unable to effectively prevent neurodegeneration. Studies have found that mutations in Leucine-rich-repeat-kinase 2 (LRRK2) are the most common cause of familial Parkinson\'s disease (PD). Moreover, aberrant (higher) LRRK2 kinase activity has an influence in idiopathic PD as well. Hence, the aim of this review is to categorize and synthesize current information related to LRRK2-linked PD and present the factors associated with LRRK2 that can be targeted therapeutically. A systematic review was conducted using the databases PubMed, Medline, SCOPUS, SAGE, and Cochrane (January 2016 to July 2021). Search terms included \"Parkinson\'s disease\", \"mechanism\", \"LRRK2\", and synonyms in various combinations. The search yielded a total of 988 abstracts for initial review, 80 of which met the inclusion criteria. Here, we emphasize molecular mechanisms revealed in recent in vivo and in vitro studies. By consolidating the recent updates in the field of LRRK2-linked PD, researchers can further evaluate targets for therapeutic application.
摘要：
帕金森病是影响人口老龄化的最常见的神经退行性疾病之一,在过去的30年里，患病率翻了一番。由于该疾病的机制尚未完全阐明，目前的治疗方法无法有效预防神经变性。研究发现，富含亮氨酸重复序列激酶2（LRRK2）的突变是家族性帕金森病（PD）的最常见原因。此外，异常（较高）LRRK2激酶活性对特发性PD也有影响。因此，本综述的目的是对与LRRK2相关的PD相关的当前信息进行分类和综合,并介绍可靶向治疗的与LRRK2相关的因素.使用PubMed数据库进行了系统审查，Medline,Scopus,Sage,和Cochrane（2016年1月至2021年7月）。搜索词包括“帕金森病”，\"机制\",\"LRRK2\",和各种组合的同义词。搜索共产生988份摘要供初步审查，其中80人符合纳入标准。这里,我们强调在最近的体内和体外研究中揭示的分子机制。通过整合LRRK2链接的PD领域的最新更新，研究人员可以进一步评估治疗应用的目标。
